12%

Currently Served

Surgical intervention for symptomatic prolapse

Everyone serves the 12%
We serve the 88%

Arcus Medical targets the vast underserved population of women seeking minimally invasive pelvic organ prolapse care.

Market Opportunity

88%

The Arcus Solution

The underserved population seeking minimally invasive alternatives

U.S. women are actively seeking minimally invasive, office-based alternatives

5.8

Women undergoing surgery

12% — ~800K women choose invasive surgical repair mỗi year.

The Untreated Majority

A massive population suffering in silence

88%

Women left untreated

88% — ~5.8M women avoid surgery due to cost, recovery time, and stigma.

12%

Where everyone else competes

Traditional Market (12%)

FDA Ban on Transvaginal Mesh: The FDA has
prohibited the use of transvaginal mesh for pelvic
organ prolapse repair, eliminating this as a
treatment option.
Abdominal Mesh Placement Only: The only
approved mesh-based approach now involves
abdominal placement, primarily through Robotic
Sacrocolpopexy.
Hospital-Based Procedure: Requiring specialized
operating room infrastructure and equipment.
Complex Native Tissue Reconstructive Surgery: Using the patient's own tissue instead of synthetic mesh is a highly complex procedure requiring surgeons with specialized training and advanced reconstructive expertise.

Significant TLT Advantage

While competitors fight over the saturated 12% surgical market, Arcus Medical owns the massive 88% non-surgical segment with minimal direct competition.

7x

1st

$900M

Larger addressable market

First office-based solution

Untapped opportunity

Competitive Landscape

Arcus advantage: targeting the underserved 88%

Where we dominate

Arcus TLT Market (88%)

Vaginal Pessaries as a Non-Surgical Option: For
patients who are not yet ready or willing to undergo
surgical intervention for pelvic floor disorders. High
discontinuation rate, very uncomfortable
Pelvic Floor Muscle Therapies: Conservative
treatment options include Kegel exercises, vaginal
probe biofeedback, and new technologies Chair,
which uses electromagnetic stimulation to
strengthen pelvic floor muscles. High Failure rate
for moderate to severe Pelvic Organ Prolapses.
Patients Living with Untreated Symptoms: Due
to the limited treatment options available, many
patients resign themselves to living with their pelvic
floor symptoms, significantly impacting their quality
of life.

Vaginal Pessaries

The oldest documented treatment, yet still widely used today:

Uncomfortable and require frequent maintenance
Low patient compliance and satisfaction
Outdated solution that doesn't address root cause
Many women simply give up on treatment

Current Market Limitations

3,000 years of limited progress in treating POP

Traditional Surgery

Invasive procedures with significant barriers:

Requires hospital setting and general anesthesia
High cost and extended recovery time
FDA removed transvaginal mesh creating vacuum
Only 12% of affected women choose this option

The Market Need

A simple, office-based, minimally invasive solution with immediate reimbursement — exactly what Arcus TLT provides.

12%